文献速递疝与腹壁外科围术期管理与 ERAS

腹股沟疝修补术围术期抗血小板与抗凝治疗的安全性与风险评估:系统综述

The safe and risk assessment of perioperative antiplatelet and anticoagulation therapy in inguinal hernia repair, a systematic review.
PubMed 文献 · Surg Endosc · 2019-07-15

结果显示,继续使用抗血小板药(阿司匹林或氯吡格雷)不增加出血并发症,与对照相似;华法林抗凝在INR<3时出血相关并发症率相似,INR>3时术后血肿发生率增加。结论建议开放和腹腔镜腹股沟疝修补术无需停用抗血小板药,华法林继续或停用需个体化决策。

要点

  • 继续使用抗血小板药(阿司匹林或氯吡格雷)不增加出血并发症。
  • 华法林抗凝在INR<3时出血并发症率与对照相似。
  • INR>3时术后血肿发生率增加,华法林管理需个体化。

核心结论

  • 开放和腹腔镜腹股沟疝修补术无需停用抗血小板治疗(阿司匹林或氯吡格雷)。
  • 华法林抗凝的继续或停用应基于有限证据和患者个体情况逐例决定。

研究设计与样本

  • 系统综述,检索PubMed、Embase、Springer和Cochrane Library截至2019年1月发表的文献。

主要发现

  • 3项研究报道停用抗血小板药、6项研究报道继续使用,与对照相比出血并发症发生率相似。
  • 6项研究报道继续华法林抗凝、2项研究检查术前3天停用华法林,在INR<3时术后出血相关并发症率相似。
  • INR>3时术后血肿发生率增加。

关键数值与推荐

  • 继续抗血小板治疗(阿司匹林或氯吡格雷)与对照相比出血并发症发生率相似。
  • 继续华法林抗凝或术前3天停用,在INR<3时术后出血相关并发症率相似。
  • INR>3时术后血肿发生率增加。

临床怎么用

  • 择期腹股沟疝修补术围术期可继续使用阿司匹林或氯吡格雷。
  • 使用华法林的患者需根据INR和个体情况决定继续或停用,INR应控制在<3。

局限性

  • 患者病情复杂,华法林管理需个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a lack of consensus on the continuation or cessation of perioperative antiplatelet and anticoagulation therapies in inguinal hernia repair, therefore, the local hospital protocols dealing with these agents vary. The aim of this study is to investigate the risk and safety of perioperative antiplatelet and anticoagulation therapies in patients undergoing elective inguinal hernia repair. METHODS: The major databases (PubMed, Embase, Springer, and Cochrane Library) were searched, and all studies published through January 2019 were identified, using the keywords Aspirin, Clopidogrel, Warfarin, antiplatelet, anticoagulation, inguinal hernia repair, bleeding, hematoma, complications. All relevant articles and reference lists in these original studies were also obtained from the above databases. RESULTS: Thirteen articles were identified, ten studies reported the results of perioperative application of antiplatelet therapy during inguinal hernia repair, nine trials reported the outcomes perioperative use of anticoagulation therapy in inguinal hernia repair, and six articles reported the results of both agents. One study did not indicate the perioperative cessation or continuation of the corresponding agents. Cessation of antiplatelets was reported in three studies and continuation of antiplatelets was used in six studies, they all demonstrated similar incidence of the bleeding complications, as compared with controls. Continued perioperative anticoagulation with Warfarin was reported in six studies and Warfarin discontinuation 3 days prior to operation was examined in two studies, both reported similar postoperative bleeding-related complication rates providing international normalized ratio (INR) < 3, and the postoperative hematoma incidence increased in the condition of INR > 3. CONCLUSION: Our results indicated that, for both open and laparoscopic inguinal hernia repair, there is no need to stop the antiplatelet therapy (Aspirin or Clopidogrel), and due to the limited evidence and the complexity of each patient' condition, the continuation or cessation of anticoagulation with Warfarin should be tailored on a case-by-case basis.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Li J, Wang M, Cheng T, et al. The safe and risk assessment of perioperative antiplatelet and anticoagulation therapy in inguinal hernia repair, a systematic review. Surg Endosc. 2019. PMID: 31309311. doi:10.1007/s00464-019-06956-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。